Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
25 Setembro 2023 - 9:00AM
Business Wire
RightSource is Charles River’s purpose-built lab offering that
provides accessible GMP quality control testing next to the
manufacturing floor
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the opening of another RightSourceSM facility, and first
in the United Kingdom, which will provide services to the Stevenage
advanced therapies biocluster. RightSource is a flexible biologics
testing lab, operated and managed by Charles River, making fast,
reliable quality control (QC) more accessible to a broader reach of
companies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230925736631/en/
RightSource provides clients with enhanced turnaround times by
bringing testing closer to manufacturing facilities, providing
industry-leading capabilities without delays caused by shipping
samples. This platform-based QC lab will be operated by Charles
River employees who will utilize Charles River’s quality management
systems, test methods, and standard operating procedures (SOPs) to
support QC testing needs.
“Traditional testing paradigms place the burden on the
client—from developing processes and upfront lab setup costs to
bearing responsibility for regulatory compliance,” said Ian Wyllie,
Director Operations, RightSource, Charles River. “The RightSource
business model significantly reduces that burden. By leveraging our
flexible testing platform and robust scientific expertise, clients
gain direct access to industry-leading biologics testing, located
next to their manufacturing operations.”
Matthew Durdy, Chief Executive of the Cell and Gene Therapy
Catapult (CGT Catapult), an independent innovation and technology
organization specializing in the advancement of cell and gene
therapies, said: “This new facility is a valuable addition to the
advanced therapies infrastructure in Stevenage. By bringing further
quality control testing into the Stevenage bioscience cluster, the
facility will enable more advanced testing to take place locally,
reducing the turnaround time and cost for cell and gene therapy
developers to manufacture their products in the area.”
Charles River and the CGT Catapult have announced a
collaboration to help the companies based at CGT Catapult’s
Stevenage Manufacturing Innovation Centre increase their
productivity by working with RightSource services. CGT Catapult
will assist its collaborators by providing streamlined and
frictionless sample transfers and digital integration.
One Operating Model, Multiple Applications
RightSource also offers a fully dedicated lab-in-a-box solution
for biopharmaceutical companies who are looking to have QC testing
carried out onsite. While RightSource Stevenage offers
decentralized testing proximal to biotech hubs, the lab-in-a-box
solution offers individual clients the convenience of in-facility
testing. Unlike standard insourcing solutions, RightSource offers
clients the complete Charles River package of proprietary assays
with all of the associated quality, scientific, and digital
platforms. Having a RightSource program in-house enables clients to
have their own dedicated QC team without the hassle of building or
maintaining it themselves.
As Charles River continues investing in digitalization, all
RightSource clients will automatically receive enhanced products
and services, increasing the value of the partnership as time goes
on. The RightSource Stevenage lab will be operational in the fourth
quarter of 2023.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development, and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
About the Cell and Gene Therapy Catapult
The Cell and Gene Therapy Catapult is an independent innovation
and technology organisation committed to the advancement of cell
and gene therapies with a vision of a thriving industry delivering
life changing advanced therapies to the world. Its aim is to create
powerful collaborations which overcome challenges to the
advancement of the sector. The Cell and Gene Therapy Catapult works
with Innovate UK. For more information, please visit
https://ct.catapult.org.uk/ or
https://www.ukri.org/councils/innovate-uk/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925736631/en/
Investors: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media: Amy Cianciaruso Corporate Vice President &
Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
FTI Consulting for the Cell and Gene Therapy Catapult
Alexander Davis +44 (0) 203 727 1729 /
Alexander.Davis@fticonsulting.com George Kendrick +44 (0) 203 727
1411 / George.Kendrick@fticonsulting.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024